Clinical and histological findings following the application of a single session of recombinant enzymes on the face

Julio Alberto Giraldo Mesa — 2026-01-15

Introduction: Several factors influence the quality and appearance of the skin, including age, lifestyle, sun exposure, and certain conditions. These elements can have a significant negative impact on some individuals. As a
result, esthetic medicine is increasingly sought after as a solution to counteract these effects, enhancing both
appearance and self-esteem. The objective of the research was to observe the clinical and histological changes
in the skin of five women with photoaging, hyperpigmentation, rhytidosis, or acne scars after a single application
of recombinant enzymes.
Methods: This longitudinal descriptive study was conducted on 5 women aged 47-65, randomly selected.
Photographic records and biopsies were taken before and after the treatment.
Results: Clinical results revealed a significant improvement in skin quality and texture, with reduced skin laxity
and skin repositioning, as well as a decrease in hyperpigmented lesions and acne scars. Histologically, there was a
reduction in hyperkeratosis and collagen basophilia, along with regeneration of elastic and collagen fibers, showing
an increase in their integrity.
Conclusion: A single dose of recombinant enzymes demonstrated improvement in skin quality both clinically and
histologically in 100% of the patients, proving to be a safe, reliable, and easy-to-apply treatment. It achieved high
levels of patient satisfaction, suggesting its potential to replace more invasive procedures.

Management of refractory metastatic colorectal cancer: consensus recommendations from Italian oncologists

Fortunato Ciardiello — 2026-01-23

Introduction: Metastatic colorectal cancer (mCRC) constitutes approximately 10% of all cancers globally and
ranks as the second leading cause of cancer-related deaths. Management of refractory mCRC remains challenging
due to pharmacological resistance and limited effective therapeutic options.
Methods: This publication presents insights from a Delphi panel of Italian clinicians regarding mCRC therapeutic
approaches, unmet medical needs, and fruquintinib’s potential clinical utility within existing treatment
algorithms. The project, guided by four leading Italian oncology experts, involved two survey rounds among 14
oncologists, achieving consensus on 15 statements with a 100% response rate.
Results: The expert panel identified critical epidemiological patterns in mCRC, with 20-25% of patients requiring further treatment after the failure of third-line therapy. The panel emphasized the clinical significance of fruquintinib’s efficacy and tolerability profile demonstrated in the FRESCO-2 trial. The experts unanimously endorsed fruquintinib as a new standard of care for adult mCRC patients who have progressed through available standard therapies.
Conclusions: This recommendation is based on fruquintinib’s observed survival benefit and manageable toxicity
profile, which facilitate improved treatment management and potentially enhance patient quality of life. The
structured consensus approach validates these recommendations, providing practical guidance for optimizing
outcomes as therapeutic options for mCRC continue to expand in complexity.

AboutOpen

Clinical and histological findings following the application of a single session of recombinant enzymes on the face

Management of refractory metastatic colorectal cancer: consensus recommendations from Italian oncologists